Introducing Journavx: the FDA-approved non-opioid, non-addictive drug for acute pain. A major breakthrough in pain medication ...

The FDA on Thursday approved a new class of pain medication that provides an alternative to opioids. It will be sold under ...

The new drug will carry a list price of $15.50 per pill, making it many times more expensive than comparable opioids.

The drug offered more relief than a placebo in clinical trials, though it does not appear more effective than other pain ...

Health insurance has increasingly become an unsustainable financial burden due to steep premium hikes and rising claim rejections. The Insurance Regulatory and Development Authority's failure to ...

In this context, identifying small-cap stocks with insider action can be an intriguing strategy for investors seeking potentially undervalued opportunities amidst stable market conditions.

In this environment, identifying promising small-cap stocks that are perceived as undervalued can offer investors potential opportunities for growth, especially when there is notable insider activity ...

The Supreme Court action has already frozen assets, including $836,000 in cash, bank accounts and four properties that authorities allege are linked to Oliver Bailey. The state could ultimately ...

In this dynamic environment, identifying small-cap stocks that are perceived as undervalued and exhibit insider activity can be a strategic approach for investors seeking opportunities in less ...